Mizuho's Positive Outlook on Amgen's Innovative Pipeline and Market Prospects
Money

Mizuho's Positive Outlook on Amgen's Innovative Pipeline and Market Prospects

authorBy Bola Sokunbi
DateJul 01, 2026
Read Time2 min
This article examines Mizuho's updated analysis of Amgen Inc. (NASDAQ: AMGN), focusing on the pharmaceutical giant's promising drug pipeline, particularly MariTide and olpasiran. It delves into Mizuho's rationale for increasing its price target and highlights key catalysts and potential challenges for Amgen in the coming years.

Unlocking Future Growth: Amgen's Pipeline Innovations Drive Mizuho's Optimism

Mizuho Elevates Amgen's Price Target Amidst Promising Drug Developments

Mizuho has revised its price target for Amgen Inc. (NASDAQ: AMGN) upwards to $303 from $295, while maintaining a 'Neutral' rating. This adjustment reflects the firm's confidence in Amgen's robust pipeline, with particular emphasis on the therapeutic potential of MariTide and olpasiran.

The Strategic Impact of Lp(a) Research on Amgen's Market Position

Mizuho highlighted that the anticipated completion of Novartis and Ionis Pharmaceuticals' Phase 3 Lp(a) research in early 2026 could significantly benefit Amgen Inc. (NASDAQ: AMGN). The outcome of this research is expected to reshape market perceptions and valuations within the cardiovascular therapeutics space.

Anticipated Market Shift: Olpasiran Takes Center Stage

Following a slight increase in Amgen Inc.'s (NASDAQ: AMGN) medium-term sales projections, Mizuho foresees a shift in investor focus towards olpasiran. This heightened attention is expected once data from the Novartis and Ionis Phase 3 Lp(a) research becomes available, likely in the first half of 2026. The release of olpasiran's own clinical data is expected to follow later.

Navigating Potential Headwinds: Amgen's IRS Tax Dispute

Despite the positive pipeline outlook, Mizuho acknowledged a potential risk stemming from a tax dispute with the IRS. The firm noted that a resolution is not expected before the latter half of 2026, and further details regarding this matter are being sought to assess its full impact on Amgen Inc. (NASDAQ: AMGN).

Amgen's Core Business: A Leader in Pharmaceutical Innovation

Amgen Inc. (NASDAQ: AMGN), established in 1980 and headquartered in California, stands as a prominent drug manufacturer. The company is dedicated to delivering human therapeutics through established pharmaceutical wholesale distribution channels, reinforcing its role as a key player in the biotechnology sector.

More Articles
Money
Braze (BRZE): A Top Tech Investment for the Next Five Years
Braze Inc. (NASDAQ: BRZE) is positioned as a leading technology stock for the upcoming five years, having demonstrated significant growth in its recent financial quarter. The company announced impressive revenue growth of 30% year-over-year, reaching $211.0 million, driven by strong demand for its AI-powered customer engagement platform. With an expanded customer base of 2,713 and strategic product innovations, Braze is solidifying its role in the market, making it an attractive prospect for investors.
By Natalie PaceJul 01, 2026
Money
Devon Energy's Strategic Debt Restructuring and Market Position
Devon Energy Corporation recently finalized a significant debt exchange, consolidating its subsidiary Coterra Energy's notes under Devon's main indenture. This move streamlines the company's capital structure and reinforces its financial standing. The successful exchange offers, which saw high participation rates, position Devon as a potentially attractive value stock for investors. The new notes are unsecured obligations, ranking equally with existing debt, demonstrating a fortified financial framework for future growth and operational stability.
By Mr. Money MustacheJul 01, 2026
Money
Arrow Electronics Pioneers AI and Cloud Innovation with New Global Experience Centers
Arrow Electronics has launched global experience centers in Alpharetta and Stockholm to accelerate the adoption of AI and cloud technologies. These centers provide immersive environments for vendors and partners to test multi-vendor solutions, focusing on hybrid infrastructure, cybersecurity, and consulting. With access to over 100 pre-built solutions and expert support, partners can validate technologies and develop custom use cases, significantly boosting the success rate of proposals.
By JL CollinsJul 01, 2026
Money
The Diminishing Returns of an MBA in a Shifting Job Market
The value proposition of an MBA degree is being re-evaluated as new graduates face lower starting salaries and a tougher job market. With the median starting salary for MBA graduates projected to decrease by $5,000 this year, and AI impacting entry-level roles, the significant financial investment in an MBA requires careful consideration of its potential return amidst evolving employer expectations and a more competitive hiring landscape.
By Natalie PaceJul 01, 2026
Money
Major Financial Players Unite to Launch New Global Stablecoin
A consortium, including financial giants Visa and Mastercard, alongside Coinbase, has unveiled 'Open Standard,' a new initiative to launch a global stablecoin named Open USD. This digital currency, pegged to the U.S. dollar, aims to streamline and expand the adoption of stablecoins for businesses worldwide by offering a low-cost, high-throughput, and broadly accessible platform. The launch signals a significant push towards integrating digital assets into mainstream financial transactions, building on recent legislative efforts to regulate the crypto space.
By Ramit SethiJun 30, 2026